Abstract Outer Membrane Vesicles (OMV) have received increased attention in recent years
as a vaccine platform against bacterial pathogens. OMV from Neisseria meningitidis …

Running over timescales that span decades or centuries, the epidemiological transition
provides the central narrative of global health. In this transition, a reduction in mortality is …

، ﺎﺑ 砠 ᖠﺳ ﻮﻜﺴﻴﺴﻧاﺮﻓ يد ﺲﻳﻮﻟ، رﺎﻣﻮﻛ ﺔﺸﺋﺎﻋ، ﺰﻠﺳﺎﻛ ورﺪﻧأ، مرﺪﻨﻟ–ﻞﺒﻣﺎﻛ ﺪﻴﻣرﺎﻳد، ﺘﻴﺑ سﻼ ود، د 砠 ᖠﻴﺑ نﻮﺟ، ﻲﺠﺑرﻮﺸﻟا
ﺐﻴﺠﻧ، بﻮﺴﻟا ينﻟورﺎﻛ ﺎﻧﺎﺘﻳﻮ ﰲﻮﺻ، رﻮﺒﺴﻜﻴﻳﺮ ﻪﻳرﺪﻧآ، ﻮﻟﻮ غارﻻ، رﺎﻔﻐﻟا ﺪﺒﻋ، نﻮﻫﺎﺘﻴ سﻮﺴﻴﻴﻠﻳﺎﻫ، ﻚﻴﻠﻓ ﺎﻧﻮﻴﻓ، ﻴﻓ ﻲﺘﺴﻳﺮﻛ …‎

Vaccines have been one of the major revolutions in the history of mankind and, during the
twentieth century, they eliminated most of the childhood diseases that used to cause millions …

Summary Three bacteria—Haemophilus influenzae, Streptococcus pneumoniae, and
Neisseria meningitidis—account for most acute bacterial meningitis. Measurement of the …

The epidemiology of invasive meningococcal disease continues to change rapidly, even in
the three years since the first Meningococcal Exchange Meeting in 2008. Control of disease …

Background A serogroup A meningococcal polysaccharide–tetanus toxoid conjugate
vaccine (PsA–TT, MenAfriVac) was licensed in India in 2009, and pre-qualified by WHO in …

The utility of wild-type outer membrane vesicle (wtOMV) vaccines against serogroup B
(MenB) meningococcal disease has been explored since the 1970s. Public health …

Background An effective, affordable, multivalent meningococcal conjugate vaccine is
needed to prevent epidemic meningitis in the African meningitis belt. Data on the safety and …

Background. The conjugate vaccine against serogroup A Neisseria meningitidis (NmA),
MenAfriVac, was first introduced in mass vaccination campaigns of 1–29-year-olds in …